Cellular Biomedicine Group Engages Huntsworth Health to Build Global KOL Advocacy for Knee Osteoarthritis Stem Cell ReJoin(TM...
April 20 2015 - 9:19AM
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the
"Company"), a biomedicine firm engaged in the development of
effective treatments for degenerative and cancerous diseases, today
announced that the Company has engaged Huntsworth Health, a global
healthcare marketing and communications agency to build a global
KOL advocacy campaign for CBMG's ReJoinTM human adipose-derived
mesenchymal progenitor cell (haMPC) clinical trials for the
treatment of Knee Osteoarthritis.
"We are pleased to work with Huntsworth Health, who is uniquely
positioned to identify, profile and target KOLs and medical
investigators for our Knee Osteoarthritis ReJoinTM clinical trials
through their experienced team of international medical
professionals and build a campaign that will resonate with our key
stakeholders," commented Dr. William (Wei) Cao, Chief Executive
Officer of Cellular Biomedicine Group. "We recognize the
significance of having our clinical data validated by global
thought leaders who have meaningful influence in the social,
economic, medical, strategic and investment communities. We look
forward to broadening our communications and building support as we
expect to release full year Phase IIb clinical data on ReJoinTM in
the fourth quarter of 2015."
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of certain degenerative diseases and
cancers. Our developmental stem cell, progenitor cell, and immune
cell projects are the result of research and development by
scientists and doctors from China and the United States. Our
flagship GMP facility in China, consisting of eight independent
cell production lines, is designed, certified and managed according
to U.S. standards. To learn more about CBMG, please visit:
www.cellbiomedgroup.com
About Huntsworth Health
Huntsworth Health is a global healthcare marketing and
communications agency with seventy wholly owned offices in thirty
countries, over two hundred healthcare consultants, of which, over
seventy possesses advanced medical and scientific
degrees. Through its health and scientific focus, Huntsworth
Health deploys unmatched scientific knowledge and complete B2B and
B2C capabilities in the continuum from science to health and
wellness.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include, but are not
limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024